PTC Therapeutics, Inc. Deferred Revenue Recognized
PTC Therapeutics, Inc. (PTCT) reported Deferred Revenue Recognized of $1.40 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-04-27.
Discontinued › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2023-04-27
- PTC Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2023-03-31 was $1.40M.
- PTC Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2022-09-30 was $0.00.
- PTC Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- PTC Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- PTC Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2021 was $4.00M, a 0.00% change from fiscal 2020.
- PTC Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2020 was $4.00M, a 50.62% decline from fiscal 2019.
- PTC Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2019 was $8.10M.
- PTC Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2018 was $0.00.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 3 month as first filed | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 9 month as first filed | Contract with Customer, Liability, Revenue Recognized 12 month | Contract with Customer, Liability, Revenue Recognized 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2023-03-31 | $1.40M 10-Q · filed 2023-04-27 | ||||||
| 2022-09-30 | $0.00 10-Q · filed 2022-10-27 | $0.00 10-Q · filed 2022-10-27 | |||||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | |||||
| 2022-03-31 | $0.00 10-Q · filed 2023-04-27 | ||||||
| 2021-12-31 | $4.00M 10-K · filed 2023-02-21 | ||||||
| 2021-09-30 | $0.00 10-Q · filed 2022-10-27 | $4.00M 10-Q · filed 2022-10-27 | |||||
| 2021-06-30 | $1.90M 10-Q · filed 2022-08-04 | $4.00M 10-Q · filed 2022-08-04 | |||||
| 2021-03-31 | $2.10M 10-Q · filed 2022-05-03 | ||||||
| 2020-12-31 | $4.00M 10-K · filed 2022-02-22 | $8.10M 10-K · filed 2021-02-25 | |||||
| 2020-09-30 | $2.00M 10-Q · filed 2021-10-28 | $6.00M 10-Q · filed 2021-10-28 | |||||
| 2020-06-30 | $2.00M 10-Q · filed 2021-07-29 | $4.00M 10-Q · filed 2021-07-29 | |||||
| 2020-03-31 | $2.00M 10-Q · filed 2021-05-04 | ||||||
| 2019-12-31 | $8.10M 10-K · filed 2022-02-22 | $3.90M 10-K · filed 2020-03-02 | |||||
| 2019-09-30 | $2.30M 10-Q · filed 2020-10-29 | $69.10M 10-Q · filed 2019-10-30 | $2.30M 10-Q · filed 2020-10-29 | $207.63M 10-Q · filed 2019-10-30 | |||
| 2019-06-30 | $85.48M 10-Q · filed 2019-08-06 | $138.53M 10-Q · filed 2019-08-06 | |||||
| 2018-12-31 | $0.00 10-K · filed 2020-03-02 | ||||||
| 2018-09-30 | $53.02M 10-Q · filed 2019-10-30 | $177.17M 10-Q · filed 2019-10-30 | |||||
| 2018-06-30 | $68.17M 10-Q · filed 2019-08-06 | $124.15M 10-Q · filed 2019-08-06 | |||||
| 2018-03-31 | $55.98M 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |